Continue Or Stop post-Stroke Antihypertensives Collaborative Study "COSSACS"


Phase N/A Results N/A

Trial Description

To determine whether antihypertensive therapy should be continued or discontinued in the acute situation.


  • Antihypertensives Drug
    Intervention Desc: This category includes all BP lowering drugs in stroke prevention trials

Trial Design

Multi-centre, prospective, randomised, open, blinded-endpoint study.

Patient Involvement

Patients will receive antihypertensive therapy for a 2-week period, after which administration will be at the discretion of individual clinicians. All routine aspects of patient management with respect to investigation, acute management and rehabilitation will be continued as standard local practice.


Type Measure Time Frame Safety Issue
Primary Primary outcome will be the mortality or dependent rate (Modified Rankin Score >2) at 14 days post-stroke.
Secondary Early secondary outcome measures will include neurological and functional status, discharge destination and blood pressure levels (compared to admission) at 2 weeks. Late secondary outcome measures will include death and dependency, discharge destination and health-related quality of life at 6 months post-stroke.


The Health Foundation